APLM_OUT_1 [2025-03-31 08:14:37 -0400] 2401 Bytes | 691 tokens | Cum: 691 tkns (8.64% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 8:14:36 AM on Mon Mar 31, 2025 -0400, and I'm firing up the spotlight on Apollomics (APLM), moving from 7.61 to 12.4596. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Apollomics:

C1 - Today 08:00AM - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
C2 - Dec-20-24 08:00AM - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
C3 - Dec-10-24 04:05PM - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
C4 - Nov-21-24 08:00AM - Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
C5 - Sep-16-24 08:00AM - Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
C6 - Sep-04-24 04:05PM - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
C7 - Aug-14-24 06:00AM - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
C8 - Aug-13-24 08:00AM - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Prior AI Reports for APLM:
1. 2025-03-20 – Score: 70 – Target: 13.6300 – Highs: 11.2400 / 11.6000 / 10.89
apollomics-inc-displays-strong-momentum-amid-high-insider-ownership

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Apollomics (APLM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

APLM_OUT_3 [2025-03-31 08:14:38 -0400] 1107 Bytes | 323 tokens | Cum: 1016 tkns (12.70% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib**
Date: Today 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052245/0/en/Apollomics-and-LaunXP-Announce-Development-and-Commercialization-Agreement-for-Vebreltinib.html

March 31, 2025 08:00 ET| Source:Apollomics Inc.Apollomics Inc.

FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co., Ltd., an affiliate of LaunXP Biomedical Co., Ltd. (TWO: 6876) (“LaunXP”), announced today that the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland China,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APLM_OUT_5 [2025-03-31 08:14:40 -0400] 779 Bytes | 243 tokens | Cum: 1261 tkns (15.76% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T12:00:32Z - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - Apollom...
A2 - 2025-03-16T21:26:19Z - $APLM | Learn to Evaluate ($APLM) using the Charts (APLM)...
A3 - 2025-03-06T06:33:01Z - $APLM | ($APLM) Trading Advice (APLM)...
A4 - 2025-02-28T20:24:25Z - APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

APLM_OUT_7 [2025-03-31 08:14:44 -0400] 1099 Bytes | 322 tokens | Cum: 1585 tkns (19.81% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - Apollomics (NASDAQ:APLM), Apollomics (NASDAQ:APLMW)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/03/g44559384/apollomics-and-launxp-announce-development-and-commercialization-agreement-for-vebreltinibLaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer ("NSCLC")Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales

FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. APLM ("Apollomics"), a late-s

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APLM_OUT_9 [2025-03-31 08:14:45 -0400] 1084 Bytes | 331 tokens | Cum: 2022 tkns (25.27% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-20T13:00:00Z - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
B2 - 2024-08-14T10:00:00Z - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
B3 - 2024-03-04T12:00:00Z - Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
B4 - 2024-01-19T21:15:00Z - Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
B5 - 2024-01-17T21:30:00Z - Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
B6 - 2024-01-03T12:00:00Z - Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APLM_OUT_11 [2025-03-31 08:14:49 -0400] 901 Bytes | 255 tokens | Cum: 2279 tkns (28.49% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/20/3000556/0/en/Apollomics-Announces-Top-line-Results-for-Phase-3-Bridging-Trial-of-Uproleselan-in-China-in-Patients-with-Relapsed-or-Refractory-Acute-Myeloid-Leukemia.htmlApollomics announced that its Phase 3 bridging trial of uproleselan in China for relapsed or refractory acute myeloid leukemia did not demonstrate a favorable benefit, with the median overall survival being lower in the uproleselan arm compared to the chemotherapy-only arm.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APLM_OUT_13 [2025-03-31 08:14:50 -0400] 238 Bytes | 59 tokens | Cum: 2416 tkns (30.20% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APLM_OUT_15 [2025-03-31 08:15:06 -0400] 3189 Bytes | 826 tokens | Cum: 3245 tkns (40.56% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------+
| Volume: 3,739 | Perf Month: 17.08% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 11.75K | Perf Quarter: -32.35% | Short Float: 0.35% | ROE: -149.31% |
+--------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 0.31 | Index: - | Short Ratio: 0.22 | ROI: -262.49% |
+--------------------+-----------------------+------------------------+-------------------+
| RSI (14): 45.98 | Market Cap: 8.39M | Short Interest: 0.00M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| ATR (14): 1.07 | Shs Outstand: 10.84M | Beta: 0.77 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA20: -4.01% | Shs Float: 0.76M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA50: -4.84% | Inst Own: 1.16% | Sales past 5Y: 0.00% | Earnings: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA200: -39.90% | Insider Own: 31.31% | Employees: - | |
+--------------------+-----------------------+------------------------+-------------------+
| Perf Week: -23.13% | Insider Trans: 0.00% | Debt/Eq: 0.23 | |
+--------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.61
Average Volume: 10025.95
30-Day High: 10.39
30-Day Low: 6.31
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

APLM_OUT_17 [2025-03-31 08:15:10 -0400] 676 Bytes | 167 tokens | Cum: 3728 tkns (46.60% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

APLM_IN_19 [2025-03-31 08:15:10 -0400] 126 Bytes | 29 tokens | Cum: 3827 tkns (47.84% of 8k)
==========================================================================

====================================
[2025-03-31 08:15:10] # Analysis Completed
Elapsed Time: 34.48 seconds